Clicky

Oxford Cannabinoid Technologies Holdings Plc(OCTP)

Description: Oxford Cannabinoid Technologies Holdings Plc, a pharmaceutical company, focuses on the development of cannabinoid-based prescription medicines. Its lead drug candidate is OCT461201, a selective CB2 agonist in solid oral dosage form that is in pre-clinical development for use in the treatment of IBS-associated visceral pain, as well as neuropathic pain conditions, including post herpetic neuralgia. The company is also developing an unmodified phytocannabinoid combination for orphan indications in neuropathic pain. Oxford Cannabinoid Technologies Holdings Plc was incorporated in 2017 and is headquartered in London, the United Kingdom.


Keywords: Pharmaceutical Drugs Pain Medication Neuropathic Pain Palmitoylethanolamide Post Herpetic Neuralgia Endocannabinoids G Protein Coupled Receptors

Home Page: www.oxcantech.com

OCTP Technical Analysis

Maddox House
London, W1S 2PZ
United Kingdom
Phone: 44 20 3034 2820


Officers

Name Title
Ms. Clarissa Ann Sowemimo-Coker Interim CEO, COO, Gen. Counsel, Company Sec. & Director
Mr. Indraneil Mahapatra Co-Founder & Non-Exec. Director
Dr. John Lucas Ph.D. Exec. Officer
Eugenia Shostak Exec. Officer
Mr. Paul William Smalley Fin. Director & Director
Dr. Valentino Parravicini Chief Scientific Officer

Exchange: LSE

Country: UK

Currency: Pence sterling (p)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.6129
Price-to-Sales TTM: 0
IPO Date:
Fiscal Year End: May
Full Time Employees: 7
Back to stocks